Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Roswell Park Cancer Institute
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01174199
First received: July 30, 2010
Last updated: February 25, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)